Current Progress in Developing Plant Extract-Based Hepatoprotective Drugs to Prevent Drug-Induced Liver Injury During Tuberculosis Treatment: A Literature Review

Fenny Fenny, Joan Joan, Ardo Sanjaya, Julia Windi Gunadi

Abstract

Introduction: Anti-tuberculosis treatment (ATT) can cause drug-induced liver injury. This complication leads to disruption of tuberculosis treatment. Therefore, plant extract-based is useful in a way to prevent drug-induced liver injury due to ATT. 

Methods: This review source came from PubMed and Google Scholar. We found 59 articles with the keywords “drug-induced liver injury” AND “hepatotoxicity” in the range 2014-2024. We selected 12 articles to be reviewed in this article. 

Result: Plant extract-based in this article has several mechanisms to prevent drug-induced liver injury due to ATT. All of them contain high antioxidants. Silymarin works by blocking the effects of the enzymes catalase and glutathione peroxidase, as well as suppressing the action of lipid peroxidase which causes liver damage. Jujube, Lasianthera africana, and Telfairia occidentalis can neutralize free radicals. Trapa natans and Bacopa monnieri work from the glutathione (GSH) pathway. Bacoside and Tamarix gallica mechanisms to prevent liver injury are still unknown. Most of the herbs can decrease levels of AST, ALT, and ALP as biomarkers of liver injury significantly. 

Conclusion: Many plant extracts have the potential to prevent the incidence of drug-induced liver injury caused by ATT both in animal models and clinical trials. However, adequate dosing and sample size are required to make sure that the effects are significant. 

Keywords

drug-induced liver injury; isoniazid; plant extract-based; rifampisin

Full Text:

PDF

References

  1. World Health Organization. Tuberculosis [Internet]. World Health Organization. 2023 [cited 2024 May 24]. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis#:~:text=Tuberculosis%20(TB)%20is%20an%20infectious,been%20infected%20with%20TB%20bacteria
  2. Furin J, Cox H, Pai M. Tuberculosis. Vol. 393, The Lancet. Lancet Publishing Group; 2019. p. 1642–56.
  3. Alsayed SSR, Gunosewoyo H. Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. Int J Mol Sci. 2023 Mar 8;24(6):5202.
  4. World Health Organization. World Tuberculosis Day 2024 [Internet]. World Health Organization. 2024 [cited 2024 May 24]. Available from: https://www.who.int/campaigns/world-tb-day/2024
  5. Loddenkemper R, Lipman M, Zumla A. Clinical Aspects of Adult Tuberculosis. Cold Spring Harb Perspect Med. 2015 Feb 6;6(1):a017848.
  6. Cudahy P, Shenoi S V. Diagnostics for pulmonary tuberculosis. Postgrad Med J. 2016 Apr 1;92(1086):187–93.
  7. Merk H, Ködmön C, van der Werf MJ. Will we reach the Sustainable Development Goals target for tuberculosis in the European Union/European Economic Area by 2030? Euro Surveill. 2019 Mar;24(12).
  8. Bakare AA, Moses VY, Beckely CT, Oluyemi TI, Ogunfeitimi GO, Adelaja AA, et al. The first-line antituberculosis drugs, and their fixed-dose combination induced abnormal sperm morphology and histological lesions in the testicular cells of male mice. Front Cell Dev Biol. 2022 Dec 13;10.
  9. Sotgiu G, Centis R, D’Ambrosio L, Battista Migliori G. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med. 2015 May 1;5(5).
  10. Sileshi T, Tadesse E, Makonnen E, Aklillu E. The Impact of First-Line Anti-Tubercular Drugs’ Pharmacokinetics on Treatment Outcome: A Systematic Review. Clin Pharmacol. 2021 Jan;Volume 13:1–12.
  11. Molla Y, Wubetu M, Dessie B. Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia. Hepat Med. 2021 Jan;Volume 13:1–8.
  12. Zhao H, Wang Y, Zhang T, Wang Q, Xie W. Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study. Medical Science Monitor. 2020 Jan 22;26.
  13. Rakasiwi M, Taufik M, Pamungkas G, Amaanullah MZ, Dewantara I. Exploring the Therapeutic Benefits of Silymarin Herbal Extract as a Supplement to Pulmonary Tuberculosis Treatment: A Comprehensive Review from Laboratory to Clinical Trials. Medical Scope Journal. 2024 Feb 1;6:243–9.
  14. Limenh LW, Kasahun AE, Sendekie AK, Seid AM, Mitku ML, Fenta ET, et al. Tuberculosis treatment outcomes and associated factors among tuberculosis patients treated at healthcare facilities of Motta Town, Northwest Ethiopia: a five-year retrospective study. Sci Rep. 2024 Dec 1;14(1).
  15. Talebi A, Soltani R, Khorvash F, Jouabadi S. The effectiveness of silymarin in the prevention of anti-tuberculosis drug-induced hepatotoxicity: A randomized controlled clinical trial. Int J Prev Med. 2023;14(1):48.
  16. Maddahi SZ, Jokar A, Kamalinejad M, Behnampur N. The efficacy of Jujube syrup on the prevention of drug-induced hepatotoxicity in pulmonary tuberculosis patients: A pilot randomized double-blind placebo-controlled clinical trial. Pharmacol Res Perspect. 2022 Feb 1;10(1).
  17. Sabina EP, Peter S J, Prathap S, Geetha A. A comparison of hepatoprotective activity of Bacoside to Silymarin treatment against a combined Isoniazid and Rifampin-induced hepatotoxicity in female Wistar rats. J Histotechnol. 2019 Jul 3;42(3):128–36.
  18. Nwidu LL, Teme RE. Hot aqueous leaf extract of Lasianthera africana (Icacinaceae) attenuates rifampicin-isoniazid-induced hepatotoxicity. J Integr Med. 2018 Jul 1;16(4):263–72.
  19. Hussain T, Subaiea GM, Firdous H. Hepatoprotective evaluation of Trapa natans against drug-induced hepatotoxicity of antitubercular agents in rats. Pharmacogn Mag. 2018 Apr 1;14(54):180–5.
  20. Nwidu LL, Oboma YI. Telfairia occidentalis (Cucurbitaceae) pulp extract mitigates rifampicin-isoniazid-induced hepatotoxicity in an in vivo rat model of oxidative stress. J Integr Med. 2019 Jan 1;17(1):46–56.
  21. Prince SE, Udhaya LB, Sunitha PS, Arumugam G. Reparation of Isoniazid and Rifampicin Combinatorial Therapy-Induced Hepatotoxic Effects by Bacopa monnieri. Pharmacology. 2016 Jun 1;98(1–2):29–34.
  22. Urfi MK, Mujahid M, Badruddeen B, Rahman MA, Rahman MA. The Role of Tamarix gallica Leaves Extract in Liver Injury Induced by Rifampicin Plus Isoniazid in Sprague Dawley Rats. J Diet Suppl. 2018 Jan 2;15(1):24–33.
  23. Emrani Z, Shojaei E, Khalili H. Ginger for Prevention of Antituberculosis-induced Gastrointestinal Adverse Reactions Including Hepatotoxicity: A Randomized Pilot Clinical Trial. Phytotherapy Research. 2016 Jun 1;30(6):1003–9.
  24. Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med. 2015 Sep 23;15(1).
  25. Heo E, Kim DK, Oh SH, Lee JK, Park JH, Chung HS. Effect of prophylactic use of silymarin on anti-tuberculosis drugs induced hepatotoxicity. Tuberc Respir Dis (Seoul). 2017 Jul 1;80(3):265–9.
  26. Zhao H, Wang Y, Zhang T, Wang Q, Xie W. Drug-induced liver injury from anti-tuberculosis treatment: A retrospective cohort study. Medical Science Monitor. 2020 Mar 7;26.
  27. Zhuang X, Li L, Liu T, Zhang R, Yang P, Wang X, et al. Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: A review. Vol. 13, Frontiers in Pharmacology. Frontiers Media S.A.; 2022.
  28. Yamasaki Y, Kobayashi K, Inaba A, Uehara D, Tojima H, Kakizaki S, et al. Indirect activation of pregnane X receptor in the induction of hepatic CYP3A11 by high-dose rifampicin in mice. Xenobiotica. 2018 Nov 2;48(11):1098–105.
  29. Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update. Vol. 94, Archives of Toxicology. Springer Science and Business Media Deutschland GmbH; 2020. p. 3381–407.
  30. Huang JH, Zhang C, Zhang DG, Li L, Chen X, Xu DX. Rifampicin-induced hepatic lipid accumulation: Association with up-regulation of peroxisome proliferator-activated receptor ã in mouse liver. PLoS One. 2016 Nov 1;11(11).
  31. Kim JH, Nam WS, Kim SJ, Kwon OK, Seung EJ, Jo JJ, et al. Mechanism investigation of rifampicin-induced liver injury using comparative toxicoproteomics in mice. Int J Mol Sci. 2017 Jul 1;18(7).
  32. Grabner GF, Xie H, Schweiger M, Zechner R. Lipolysis: cellular mechanisms for lipid mobilization from fat stores. Vol. 3, Nature Metabolism. Nature Research; 2021. p. 1445–65.
  33. Xu Y, Jiang Y, Li Y. Pyrazinamide enhances lipid peroxidation and antioxidant levels to induce liver injury in rat models through PI3k/Akt inhibition. Toxicol Res (Camb). 2020;9(3):149–57.
  34. Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol. 2016 Jun;81(6):1030–6.
  35. Vargas-Mendoza N, Madrigal-Santillán E, Morales-González A, Esquivel-Soto J, Esquivel-Chirino C, García-Luna Y González-Rubio M, et al. Hepatoprotective effect of silymarin. World J Hepatol. 2014 Mar 27;6(3):144–9.
  36. Gillessen A, Hartmut H-J Schmidt. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. Adv Ther [Internet]. 37. Available from: https://doi.org/10.6084/
  37. Averill-Bates DA. The antioxidant glutathione. Vitam Horm. 2023;121:109–41.

DOI: https://doi.org/10.13057/smj.v8i1.91713

Refbacks

  • There are currently no refbacks.